Ab­b­Vie in po­si­tion to be­come largest phar­ma by 2028, nar­row­ly edg­ing out Roche — re­port

Thanks to the suc­cess of its Covid-19 vac­cine Comir­naty, Pfiz­er cur­rent­ly holds the top spot in Eval­u­ate Phar­ma’s rank­ing of phar­ma com­pa­nies by sales — but not for long, ac­cord­ing to an­a­lysts.

A new Eval­u­ate Phar­ma re­port pre­dicts that Pfiz­er will drop down four spots by 2028, with Ab­b­Vie pegged to be­come the top-sell­ing phar­ma with an es­ti­mat­ed $65.7 bil­lion in sales.

De­spite ap­proach­ing a fast-ap­proach­ing patent cliff for Hu­mi­ra, Ab­b­Vie has can­di­dates in the pipeline to re­place that lost rev­enue, such as Skyrizi, Rin­voq and Ven­clex­ta, ac­cord­ing to an­a­lysts. CEO Rick Gon­za­lez picked up on that note ear­li­er this year when he pre­dict­ed Skyrizi and Rin­voq will be­come Hu­mi­ra’s suc­ces­sors, tak­ing up all of its in­di­ca­tions plus atopic der­mati­tis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER